Kura Oncology, Inc. (KURA) Financial Statements
Kura Oncology, Inc. (KURA) reported trailing twelve-month revenue of $77.2M (up 25.2% year on year) and net income of -$296.8M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$117.4M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
KURAKura Oncology, Inc.Follow KURA — free
—
Price chart with a free account
- Market cap
- 854.9M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|
| Revenue | 53.9 | 67.5 | 77.2 | |
| Gross profit | — | 67.4 | — | |
| Research & development | 170.0 | 251.1 | 259.5 | |
| Operating income | -193.2 | -303.6 | -318.1 | |
| Pre-tax income | -172.0 | -278.4 | -296.7 | |
| Income tax | 2.0 | 0.3 | 0.1 | |
| Net income | -174.0 | -278.7 | -296.8 | |
| Diluted EPS ($) | -2.02 | -3.18 | -3.37 | |
| Diluted shares (mn) | 86.2 | 87.7 | — |
USD millions · SEC XBRL
Kura Oncology, Inc. — questions
- What is Kura Oncology, Inc.'s revenue?
- $77.2M over the twelve months to 2026-06-30, up 25.2% year on year, from its 10-Q and 10-K filings.
- What is Kura Oncology, Inc.'s net income?
- -$296.8M over the twelve months to 2026-06-30.
- What is Kura Oncology, Inc.'s free cash flow?
- -$117.4M over the twelve months to 2026-06-30.
- What are Kura Oncology, Inc.'s diluted earnings per share?
- $-3.37 over the twelve months to 2026-06-30.
Every figure on this page comes from Kura Oncology, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.